Walleye Capital Adds $5M in ANI Pharmaceuticals, Inc. ($ANIP)
Key Points
- Walleye Capital changed its ANI Pharmaceuticals, Inc. ($ANIP) stake by 56.1% last quarter, boosting to 183,075 shares worth $14.95 million.
- Wall Street's consensus rating on $ANIP is Strong Buy and an average price target of $112.71.
- $ANIP last traded around $81.68.
Walleye Capital increased its position in ANI Pharmaceuticals, Inc. ($ANIP) by 56.1% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 183,075 shares of ANI Pharmaceuticals, Inc. after buying 65,768 shares during the quarter. Walleye Capital's holdings in ANI Pharmaceuticals, Inc. were worth $14.95 million as of its most recent filing.
ANI Pharmaceuticals, Inc. ($ANIP) Stock
ANI Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.